February 6, 2017
Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.
Date: Effective immediately, February 6, 2017
If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com